KromaTiD Blog2023-03-22T10:28:23-06:00

KromaTiD’s Dark Lab Files: A Blog

In Situ 3D Scaffold-Mediated T-Cell Transduction

Use of three-dimensional (3D) scaffolds in vivo to influence cell behavior is not a new concept. However, recently reported work innovatively applies the approach to the field of cancer immunotherapy1. The use of 3D scaffolds loaded with lentiviral vectors (LVs) to program host T-cells [...]

March 1, 2024|Tags: , , , , |

Natural Killer T (NKT) Cells in Cancer Immunotherapy

While T cells engineered with chimeric antigen receptors (CAR-T cells) have revolutionized the landscape of hematologic malignancy treatment, their efficacy against solid tumors remains limited. However, there is a promising alternative: Natural Killer T (NKT) cells. These innate-like T lymphocytes are unique contenders in [...]

Automating CAR-NK Cell Manufacturing

Acute myeloid leukemia (AML) is a neoplastic process characterized by its aggressive nature and limited treatment options. Too many AML patients are unable to achieve long-term remission with current therapies, fueling the search for novel strategies. CAR-NK cells offer a compelling solution, leveraging the [...]

February 16, 2024|Tags: , , |

SynNotch-CAR T Cells vs. Glioblastoma

Glioblastoma multiforme (GBM), the deadliest malignant brain tumor, also represents a large proportion of all cerebral neoplasms1. Despite strides in immunotherapy, including Chimeric Antigen Receptor (CAR)-T cells, challenges like on-target off-tumor toxicity, the blood-brain barrier, and the immunosuppressive tumor microenvironment (TME) have hindered progress. [...]

February 9, 2024|Tags: , , , |

Stony Brook Study on the Role of DNA Amplification in Cancer Chemoresistance Leverages KromaTiD dGH in-Site™ Technology

[Longmont, CO. February 6, 2024] —A Stony Brook University team of researchers led by Gábor Balázsi, PhD, has identified DNA amplification as a major cause of drug resistance in engineered mammalian cell lines and has identified a novel approach to overcome it in those [...]

February 7, 2024|Tags: , , , |

Title

Go to Top